Galmed Pharmaceuticals (GLMD) Profit After Tax (2013 - 2026)

Galmed Pharmaceuticals' Profit After Tax history runs 14 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 73.01% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $490000.0 (up 189.25% YoY), while the FY2025 annual figure was -$316000.0, up 16.4% from the prior year.
• Profit After Tax for Q1 2026 stood at $1.9 million, up from -$5.8 million in the prior quarter.
• The five-year high for Profit After Tax was $5.4 million in Q3 2022, with the low at -$33.7 million in Q4 2022.
• The 5-year median for Profit After Tax is $1.1 million (2024), against an average of -$2.5 million.
• The sharpest annual moves came in 2023 and 2025: Profit After Tax plunged 72.47% in 2023, then soared 186.59% in 2025.
• Galmed Pharmaceuticals' Profit After Tax stood at -$33.7 million in 2022, then soared by 64.93% to -$11.8 million in 2023, then surged by 60.32% to -$4.7 million in 2024, then decreased by 23.92% to -$5.8 million in 2025, then soared by 132.89% to $1.9 million in 2026.
• Business Quant data shows GLMD's Profit After Tax at $1.9 million in Q1 2026, -$5.8 million in Q4 2025, and $1.9 million in Q3 2025.